These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33086721)

  • 1. Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer.
    Papadimitropoulou A; Vellon L; Atlas E; Steen TV; Cuyàs E; Verdura S; Espinoza I; Menendez JA; Lupu R
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
    Menendez JA; Mehmi I; Papadimitropoulou A; Vander Steen T; Cuyàs E; Verdura S; Espinoza I; Vellon L; Atlas E; Lupu R
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
    Menendez JA; Mehmi I; Lupu R
    Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells.
    Tang CK; Perez C; Grunt T; Waibel C; Cho C; Lupu R
    Cancer Res; 1996 Jul; 56(14):3350-8. PubMed ID: 8764133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.
    Aceto N; Duss S; MacDonald G; Meyer DS; Roloff TC; Hynes NE; Bentires-Alj M
    Breast Cancer Res; 2012 Oct; 14(5):R131. PubMed ID: 23062209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling.
    Yang L; Vander Steen T; Espinoza I; Cuyàs E; Verdura S; Menendez JA; Lupu R
    Am J Cancer Res; 2022; 12(5):2173-2188. PubMed ID: 35693067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.
    Grunt TW; Saceda M; Martin MB; Lupu R; Dittrich E; Krupitza G; Harant H; Huber H; Dittrich C
    Int J Cancer; 1995 Nov; 63(4):560-7. PubMed ID: 7591267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her-2/neu-induced "cytokine signature" in breast cancer.
    Vazquez-Martin A; Colomer R; Menendez JA
    Adv Exp Med Biol; 2008; 617():311-9. PubMed ID: 18497054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Menendez JA; Mehmi I; Lupu R
    J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
    Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
    Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells.
    Vadlamudi R; Adam L; Tseng B; Costa L; Kumar R
    Cancer Res; 1999 Jun; 59(12):2843-6. PubMed ID: 10383144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression.
    Ruan SQ; Wang SW; Wang ZH; Zhang SZ
    Mol Med Rep; 2012 Jul; 6(1):131-8. PubMed ID: 22576740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
    Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
    Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
    Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells.
    Yamashita N; Saito N; Zhao S; Terai K; Hiruta N; Park Y; Bujo H; Nemoto K; Kanno Y
    Exp Cell Res; 2018 May; 366(1):34-40. PubMed ID: 29501698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.
    Ruan SQ; Wang ZH; Wang SW; Fu ZX; Xu KL; Li DB; Zhang SZ
    Biochem Biophys Res Commun; 2012 Apr; 420(2):385-90. PubMed ID: 22425775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.
    Asrani K; Keri RA; Galisteo R; Brown SA; Morgan SJ; Ghosh A; Tran NL; Winkles JA
    Mol Cancer Res; 2013 Apr; 11(4):393-404. PubMed ID: 23378579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.